A biomedical revolution is here. Researchers can now target drugs at the molecular roots of diseases. Combined with advances in computing power and predictive analytics, companies and physicians can tailor complex treatment regimens to a patient’s unique biology.

Recommended Stories

The FDA changes the rules — rare disease patients pay with their lives

FDA’s ‘accelerated approval’ pathway for drugs is important but imperfect

Experimental Alzheimer’s drug slows cognitive decline in late-stage study